Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
← catalyst calendarNCT06995677 · readout ≤ 559 d
Sponsored by Tyra Biosciences, Inc (industry) · TYRA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
47
Countries
Australia, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-27 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Low-grade NMIBC
- FGFR Gene Amplification
- FGFR Gene Alterations
- FGFR3 Gene Alteration
- FGFR3 Gene Mutation
- FGFR3 Gene Fusions
Interventions
- Drug: TYRA-300 60mg
- Drug: TYRA-300 50mg
- Drug: TYRA-300 Dose TBD
Primary outcome
what the primary-completion date above is the date OFTo assess the efficacy of TYRA-300 in LG IR-NMIBC participants
measured at 3 months
Permalink · TYRA's whole pipeline · Catalyst calendar · Every registered study · What changed